Florastamin

Phase 3Small molecule

HHTA Co., Ltd.

Florastamin is one of 69 small molecule programs targeting Metastatic Prostate Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic Prostate CancerActive, not recruiting

Prostate CancerActive, not recruiting

Metastatic Prostate CancerPhase 3

Active, not recruiting

Prostate CancerPhase 3

Active, not recruiting

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Florastamin

HHTA Co., Ltd.

Phase 3

2 2

Novantrone

Pfizer

Preclinical

5 3

Mekinist

Novartis

Preclinical

3 4

Trexall

Alnylam Pharmaceuticals

Preclinical

—5

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

2 6

Duragesic

CCephalon

Preclinical

1 7

Ranexa

MMenarini International Operations Luxembourg SA

Preclinical

1 8

Prednisone/prednisolone

Roche

Preclinical

3 9

Triptorelin Pamoate

Ipsen

Preclinical

2 10

Osmitrol

BB. Braun Medical Inc.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Prostate Cancer2 trials

Study of 18F-Florastamin PET/CT Imaging in Patients With at Least Intermediate Risk Prostate Cancer

Unknown status·HHTA Co., Ltd.·Phase 3·NCT06011304·267 enrolled

Study of 18F-Florastamin PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer

Recruiting·HHTA Co., Ltd.·Phase 3·NCT06754085·131 enrolled

PET/CT Imaging1 trial

Evaluate the Clinical Usefulness of [F-18]Florastamin PET/CT Imaging Diagnosis Compared to MRI Diagnosis

Active, not recruiting·FFutureChem·Phase 3·NCT05004285·398 enrolled

Metastatic Prostate Cancer1 trial

[18F]Florastamin PET/CT Imaging Examination in Patients With Suspected Recurrent or Metastatic Prostate Cancer

Active, not recruiting·FFutureChem·Phase 3·NCT05936658·138 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Florastamin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Florastamin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Florastamin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — HTA Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: HHTA Co., Ltd.

Florastamin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Prostate Cancer2 trials

PET/CT Imaging1 trial

Metastatic Prostate Cancer1 trial

References

Drug Info

Quick Facts

Related News